We are empowered by our technical expertise in structure-based drug design and our innovative drug discovery engine, which allows us to address unmet medical need by targeting key psoriatic pathways. These core competencies have allowed us to screen and develop natural product  and small molecule support therapies targeted at antimicrobial proteins specifically S100, IL6 and TNF-α next-generation cell signaling inhibitors to prevent and support cure psoriasis. We have two completed or ongoing international registrational trials.